Athanasios G Tzioufas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11876064/publications.pdf

Version: 2024-02-01

202 papers

9,592 citations

28190 55 h-index ⁴²²⁹¹ **92**

g-index

206 all docs 206 docs citations

206 times ranked 10159 citing authors

#	Article	IF	CITATIONS
1	Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. Rheumatology, 2022, 61, 1639-1644.	0.9	17
2	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	1.9	7
3	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. European Respiratory Journal, 2022, 60, 2102951.	3.1	56
4	Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981–2021). Rheumatology, 2022, 61, 3576-3585.	0.9	19
5	Kinetics of Mononuclear Cell Subpopulations in the Peripheral Blood of Patients with Giant Cell Arteritis During the Acute Phase of the Disease: The Role of Steroids. Mediterranean Journal of Rheumatology, 2022, 33, 102.	0.3	O
6	Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies. Frontiers in Endocrinology, 2022, 13, 860880.	1.5	5
7	A past medical history of autoimmune disease predicts a future with fewer relapses in patients with ANCA-associated vasculitis. Clinical and Experimental Rheumatology, 2022, 40, 741-750.	0.4	O
8	Late and booster <scp>antiâ€SARSâ€CoV</scp> â€2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by <scp>XXX</scp> et al. ACR Open Rheumatology, 2022, 4, 645-646.	0.9	1
9	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2022, 131, 102846.	3.0	6
10	Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. Autoimmunity Reviews, 2021, 20, 102742.	2.5	8
11	DNA Methylation Studies in Saliva of Patients with Sjögren's Syndrome. Mediterranean Journal of Rheumatology, 2021, 32, 176.	0.3	1
12	A computational workflow for the detection of candidate diagnostic biomarkers of Kawasaki disease using time-series gene expression data. Computational and Structural Biotechnology Journal, 2021, 19, 3058-3068.	1.9	8
13	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome. Journal of Clinical Medicine, 2021, 10, 644.	1.0	7
14	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	1.3	4
15	New frontiers in precision medicine for Sjogren's syndrome. Expert Review of Clinical Immunology, 2021, 17, 127-141.	1.3	10
16	A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness. Vaccine, 2021, 39, 1593-1597.	1.7	5
17	Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. International Journal of Molecular Sciences, 2021, 22, 4099.	1.8	3
18	SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study. Viruses, 2021, 13, 1143.	1.5	13

#	Article	lF	Citations
19	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. Frontiers in Immunology, 2021, 12, 683623.	2.2	6
20	Deregulation of the Kallikrein Protease Family in the Salivary Glands of the Sjögren's Syndrome ERdj5 Knockout Mouse Model. Frontiers in Immunology, 2021, 12, 693911.	2.2	5
21	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. Computers in Biology and Medicine, 2021, 134, 104520.	3.9	10
22	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	3.0	24
23	Occurrence and Antigenic Specificity of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) in Systemic Autoimmune Diseases. Cells, 2021, 10, 2128.	1.8	3
24	Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 705079.	2.2	8
25	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Frontiers in Immunology, 2021, 12, 719023.	2.2	28
26	Hypocomplementemia at Diagnosis of Pauci-immune Glomerulonephritis Is Associated With Advanced Histopathological Activity Index and High Probability of Treatment Resistance. Kidney International Reports, 2021, 6, 2425-2435.	0.4	13
27	COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. Journal of Autoimmunity, 2021, 123, 102687.	3.0	19
28	Machine Learning Approaches on High Throughput NGS Data to Unveil Mechanisms of Function in Biology and Disease. Cancer Genomics and Proteomics, 2021, 18, 605-626.	1.0	11
29	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	3.0	45
30	Sjogren's Syndrome (Ss) in Progressive Systemic Sclerosis (SSc). In Clinical Practice, 2021, , 281-297.	0.1	0
31	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
32	Searching for the "X factor" in Sjögren's syndrome female predilection. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
33	Idiopathic retroperitoneal fibrosis: clinical features, treatment modalities, relapse rate in Greek patients and a review of the literature. Clinical and Experimental Rheumatology, 2021, , .	0.4	1
34	Patient-reported experience and health-related quality of life in patients with primary Sj \tilde{A} \P gren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
35	Multiple additive regression trees with hybrid loss for classification tasks across heterogeneous clinical data in distributed environments: a case study., 2021, 2021, 1670-1673.		4
36	A federated AI strategy for the classification of patients with Mucosa Associated Lymphoma Tissue (MALT) lymphoma across multiple harmonized cohorts. , 2021, 2021, 1666-1669.		0

3

#	Article	IF	CITATIONS
37	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 80-84.	0.4	8
38	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sjögren's Syndrome. International Journal of Molecular Sciences, 2021, 22, 13441.	1.8	1
39	Searching for the "X factor" in Sjögren's syndrome female predilection. Clinical and Experimental Rheumatology, 2021, 39, 206-214.	0.4	7
40	Patient-reported experience and health-related quality of life in patients with primary Sjögren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, 39, 123-130.	0.4	1
41	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.5	307
42	Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center. Rheumatology, 2020, 59, 1241-1246.	0.9	6
43	Common and rare forms of vasculitis associated with Sjögren's syndrome. Current Opinion in Rheumatology, 2020, 32, 21-28.	2.0	10
44	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	2.5	79
45	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers, 2020, 12, 3520.	1.7	9
46	Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia. Lancet, The, 2020, 396, 853.	6.3	2
47	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. Journal of Clinical Medicine, 2020, 9, 2620.	1.0	26
48	Salivary Gland Ultrasonography in Sj \tilde{A} ¶gren's Syndrome: A European Multicenter Reliability Exercise for the HarmonicSS Project. Frontiers in Medicine, 2020, 7, 581248.	1.2	26
49	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096.	2.2	45
50	Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?. Current Vascular Pharmacology, 2020, 18, 425-430.	0.8	3
51	Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1661-1663.	0.5	146
52	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	2.5	36
53	Overcoming the Barriers That Obscure the Interlinking and Analysis of Clinical Data Through Harmonization and Incremental Learning. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 83-90.	1.7	9
54	Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of SjĶgren's Syndrome Patients. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 49-56.	1.7	4

#	Article	IF	Citations
55	Interaction of Human Salivary Gland Epithelial Cells with B Lymphocytes: Implications in the Pathogenesis of Sjögren's Syndrome. Mediterranean Journal of Rheumatology, 2020, 31, 424.	0.3	4
56	Diagnosis and Management of a Young Girl With Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Linked to a Novel Mutation. Cureus, 2020, 12, e10766.	0.2	0
57	Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases. Current Vascular Pharmacology, 2020, 18, 533-537.	0.8	3
58	Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 29-39.	0.4	0
59	Type-III interferons in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 245-252.	0.4	2
60	EULAR Sjögren's syndrome study group: an eSSential way to address the unmet needs of the disease. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 23-24.	0.4	2
61	One year in review 2020: pathogenesis of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 3-9.	0.4	8
62	A Training Tool to support the management and diagnosis of SjA¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 174-179.	0.4	0
63	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 189-194.	0.4	0
64	Response to: â€~ls miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands?' by Nocturne et al. Annals of the Rheumatic Diseases, 2019, 78, e96-e96.	0.5	0
65	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clinical Rheumatology, 2019, 38, 125-132.	1.0	35
66	Trial of canakinumab, an IL- $1\hat{l}^2$ receptor antagonist, in patients with inclusion body myositis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e581.	3.1	17
67	Predictive markers of lymphomagenesis in Sj \tilde{A} ¶gren's syndrome: From clinical data to molecular stratification. Journal of Autoimmunity, 2019, 104, 102316.	3.0	36
68	Predicting lymphoma outcomes and risk factors in patients with primary Sjögren's Syndrome using gradient boosting tree ensembles. , 2019, 2019, 2165-2168.		8
69	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj¶gren's syndrome. RMD Open, 2019, 5, e001064.	1.8	53
70	Epigenetic perspectives on systemic autoimmune disease. Journal of Autoimmunity, 2019, 104, 102315.	3.0	50
71	Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells. Immunity, 2019, 51, 573-589.e8.	6.6	336
72	Ablation of the Chaperone Protein ERdj5 Results in a SjÃ \P gren's Syndrome-Like Phenotype in Mice, Consistent With an Upregulated Unfolded Protein Response in Human Patients. Frontiers in Immunology, 2019, 10, 506.	2.2	13

#	Article	lF	Citations
73	Medical data quality assessment: On the development of an automated framework for medical data curation. Computers in Biology and Medicine, 2019, 107, 270-283.	3.9	67
74	SP0190â€2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJöGREN‧ SYNDROME WITH TOF AND SYSTEMIC THERAPIES. , 2019, , .	PICAL	3
75	Lymphomagenesis in Sj $ ilde{A}$ gren's syndrome: Predictive biomarkers towards precision medicine. Autoimmunity Reviews, 2019, 18, 137-143.	2.5	54
76	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
77	Enhancing medical data quality through data curation: a case study in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 90-96.	0.4	2
78	Sjögren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 175-184.	0.4	4
79	Autoimmune epithelitis beyond the exocrine glands: an unusual case of anti-Ro/La and Scl-70 lymphocytic interstitial pneumonia. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 249-251.	0.4	1
80	The necessity of novel biomarkers in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 16-18.	0.4	1
81	Variation in primary Sjögren's syndrome care among European countries. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 27-28.	0.4	1
82	Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. Clinical Rheumatology, 2018, 37, 737-747.	1.0	29
83	TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients. Journal of Immunology Research, 2018, 2018, 1-8.	0.9	24
84	Towards the Establishment of a Biomedical Ontology for the Primary Sjögren's Syndrome. , 2018, 2018, 4089-4092.		4
85	How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study. Autoimmunity Reviews, 2018, 17, 1124-1133.	2.5	5
86	Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212639.	0.5	32
87	Cryoglobulinaemia. Nature Reviews Disease Primers, 2018, 4, 11.	18.1	143
88	Patient with ankylosing spondylitis and scleroderma renal crisis. Mediterranean Journal of Rheumatology, 2018, 29, 86-88.	0.3	3
89	Update on Sjögren's Syndrome 2018. Mediterranean Journal of Rheumatology, 2018, 29, 193-198.	0.3	5
90	Role of miR200b-5p miRNA in lymphomagenesis associated with Sjögren's syndrome (SS). Mediterranean Journal of Rheumatology, 2018, 29, 56-58.	0.3	2

#	Article	IF	Citations
91	Autoimmune or infectious disease? That is the question. Clinical and Experimental Rheumatology, 2018, 36, 517-518.	0.4	1
92	Limited efficacy of targeted treatments in Sjögren's syndrome: why?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 27-28.	0.4	2
93	Severe cutaneous hand infection: Mycobacterium marinum in an immunosuppressed patient. Clinical and Experimental Rheumatology, 2018, 36, 1117.	0.4	2
94	Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 239-240.	0.4	1
95	Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms. Clinical and Experimental Rheumatology, 2018, 36, 86-89.	0.4	9
96	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1161-1168.	0.5	200
97	Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 625-628.	0.5	45
98	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of Hepatology, 2017, 66, 1282-1299.	1.8	73
99	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmunity Reviews, 2017, 16, 523-541.	2.5	87
100	Insight into pathogenesis of Sj \tilde{A} ¶gren's syndrome: Dissection on autoimmune infiltrates and epithelial cells. Clinical Immunology, 2017, 182, 30-40.	1.4	67
101	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq $1\ 1\ 0.784$	1314 rgBT 2.5	/Overlock 1
102	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Scientific Reports, 2017, 7, 7354.	1.6	28
103	Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers. Immunologic Research, 2017, 65, 331-344.	1.3	37
104	07.08â€Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
105	08.37â€Thrombospondin-1 is highly expressed by salivary gland epithelial cells of sjögren's syndrome patients, both constitutively and upon exposure to necrotic cells debris. , 2017, , .		O
106	Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract. Frontiers in Genetics, 2017, 8, 65.	1.1	11
107	Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study. Clinical and Experimental Rheumatology, 2017, 35, 192-200.	0.4	4
108	Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 155-164.	0.4	1

#	Article	IF	Citations
109	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sj $ ilde{A}$ gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 719-720.	0.4	3
110	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. Journal of Autoimmunity, 2016, 72, 57-64.	3.0	6
111	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmunity Reviews, 2016, 15, 1145-1160.	2.5	87
112	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. Clinical Immunology, 2016, 173, 157-160.	1.4	24
113	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.5	1,114
114	Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. Rheumatology, 2016, 55, 789-800.	0.9	120
115	Primary SjÓ§gren's syndrome: Clinical phenotypes, outcome and the development of biomarkers. Autoimmunity Reviews, 2016, 15, 695-703.	2.5	52
116	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics, 2016, 13, 163-178.	2.1	17
117	Autoantibodies in Sjögren's Syndrome and Laboratory Markers. Rare Diseases of the Immune System, 2016, , 293-308.	0.1	1
118	Panniculitis: an unusual presenting manifestation of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 126-8.	0.4	2
119	Autoantibodies in Autoimmune Diseases: Clinical and Critical Evaluation. Israel Medical Association Journal, 2016, 18, 519-524.	0.1	9
120	A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome–Related Lymphoproliferation. Arthritis and Rheumatology, 2015, 67, 2732-2741.	2.9	60
121	Sjögren's Syndrome. , 2015, , 883-889.		O
122	Saliva proteomics is a promising tool to study Sjögren syndrome. Nature Reviews Rheumatology, 2015, 11, 202-203.	3.5	23
123	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. PLoS ONE, 2015, 10, e0116189.	1.1	77
124	Clinical picture, outcome and predictive factors of lymphoma in SjÓ§gren syndrome. Autoimmunity Reviews, 2015, 14, 641-649.	2.5	68
125	Treatment of rheumatoid arthritis: Unraveling the conundrum. Journal of Autoimmunity, 2015, 65, 1-18.	3.0	99
126	Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. Journal of Autoimmunity, 2015, 65, 30-37.	3.0	39

#	Article	IF	Citations
127	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Journal of Neuroimmunology, 2015, 289, 8-11.	1.1	30
128	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity, 2015, 48, 453-9.	1.2	6
129	Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clinical and Experimental Rheumatology, 2015, 33, 216-24.	0.4	32
130	The contribution of epigenetics in SjÃf¶grenââ,¬â"¢s Syndrome. Frontiers in Genetics, 2014, 5, 71.	1.1	60
131	Diagnostic value of ultrasonography in Sjögren's syndrome. Nature Reviews Rheumatology, 2014, 10, 450-452.	3.5	9
132	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. Journal of the Neurological Sciences, 2014, 347, 143-147.	0.3	76
133	SS-B (La) Autoantibodies. , 2014, , 247-253.		0
134	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. Journal of Autoimmunity, 2014, 51, 89-98.	3.0	99
135	A comprehensive review of autoantibodies in primary Sj \tilde{A} ¶gren's syndrome: Clinical phenotypes and regulatory mechanisms. Journal of Autoimmunity, 2014, 51, 67-74.	3.0	114
136	Classification criteria of Sjögren's syndrome. Journal of Autoimmunity, 2014, 48-49, 42-45.	3.0	58
137	Sjögren's Syndrome. , 2014, , 1069-1075.		0
138	Minor Salivary Gland Inflammatory Lesions in Sj \tilde{A} ¶gren Syndrome: Do They Evolve?. Journal of Rheumatology, 2013, 40, 1566-1571.	1.0	62
139	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. Journal of the Neurological Sciences, 2013, 334, 123-125.	0.3	51
140	Sjögren's syndrome. International Journal of Clinical Rheumatology, 2013, 8, 517-520.	0.3	1
141	Clinically Significant Renal Involvement in Primary Sjögren's Syndrome: Clinical Presentation and Outcome. Arthritis and Rheumatism, 2013, 65, 2945-2953.	6.7	129
142	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. PLoS ONE, 2013, 8, e55843.	1.1	83
143	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. Medicine (United) Tj ETQq1 :	1 0.78431 0.4	4 rgBT /Over
144	Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17609-17614.	3.3	140

#	Article	IF	CITATIONS
145	Punctal occlusion in Sjögren's syndrome needs clarification. Nature Reviews Rheumatology, 2012, 8, 752-752.	3.5	O
146	Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. Journal of Autoimmunity, 2012, 39, 234-239.	3.0	74
147	Topical and systemic medications for the treatment of primary Sj $\tilde{A}^{f q}$ gren's syndrome. Nature Reviews Rheumatology, 2012, 8, 399-411.	3.5	152
148	Classification criteria for Sjogren's syndrome: A critical review. Journal of Autoimmunity, 2012, 39, 9-14.	3.0	122
149	Pathogenesis of Sjögren's syndrome: What we know and what we should learn. Journal of Autoimmunity, 2012, 39, 4-8.	3.0	191
150	Autoantibodies in Sj \tilde{A} ¶gren's syndrome: Clinical presentation and regulatory mechanisms. Presse Medicale, 2012, 41, e451-e460.	0.8	48
151	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 798-802.	0.9	73
152	Cellular microRNAs (miRNAs) and Sjögren's syndrome: Candidate regulators of autoimmune response and autoantigen expression. Journal of Autoimmunity, 2011, 37, 129-135.	3.0	86
153	Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmuneâ€associated congenital heart block. Arthritis and Rheumatism, 2011, 63, 2783-2789.	6.7	30
154	Fine Epitope Specificity of Anti-erythropoietin Antibodies Reveals Molecular Mimicry With HIV-1 p17 Protein: A Pathogenetic Mechanism for HIV-1–Related Anemia. Journal of Infectious Diseases, 2011, 204, 902-911.	1.9	36
155	Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis. Journal of Rheumatology, 2011, 38, 1304-1308.	1.0	20
156	Pathogenetic Aspects of Primary Sjögren's Syndrome. , 2011, , 33-53.		1
157	B-cell Epitopes of Sjögren's Syndrome-Related Autoantigens Ro/SSA and La/SSB. , 2011, , 133-149.		1
158	Gynecological and Reproductive Complications in Primary Sjögren's Syndrome. , 2011, , 333-346.		0
159	Current Treatment of Extraglandular Manifestations with Disease-Modifying and Immunosuppressive Agents., 2011,, 337-344.		0
160	Sjögren syndrome. , 2011, , 1339-1350.e1.		1
161	Idiotype, anti-idiotype network of autoantibodies. Autoimmunity Reviews, 2010, 9, 631-633.	2.5	44
162	Autoimmune response and target autoantigens in Sjogren's syndrome. European Journal of Clinical Investigation, 2010, 40, 1026-1036.	1.7	63

#	Article	IF	CITATIONS
163	RNA Recognition Motif (RRM) of La/SSB: The Bridge for Interparticle Spreading of Autoimmune Response to U1-RNP. Molecular Medicine, 2010, 16, 19-26.	1.9	19
164	Current aspects of pathogenesis in Sjögren's syndrome. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 325-334.	1.2	31
165	Treatment of Primary Sjögren Syndrome. JAMA - Journal of the American Medical Association, 2010, 304, 452.	3.8	309
166	Pathogenetic mechanisms in the initiation and perpetuation of Sj \tilde{A} ¶gren's syndrome. Nature Reviews Rheumatology, 2010, 6, 529-537.	3. 5	206
167	B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: Tools to study the regulation of the autoimmune response. Journal of Autoimmunity, 2010, 35, 256-264.	3.0	59
168	Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Research and Therapy, 2010, 12, R208.	1.6	21
169	Salivary gland imaging techniques for the diagnosis of Sjögren's syndrome. International Journal of Clinical Rheumatology, 2009, 4, 321-327.	0.3	6
170	Prevalence of hepatitis C serum antibody in autoimmune diseases. Journal of Autoimmunity, 2009, 32, 261-266.	3.0	65
171	Functional expression of the alpha 2-macroglobulin receptor CD91 in salivary gland epithelial cells. Journal of Autoimmunity, 2009, 33, 141-146.	3.0	15
172	Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren's syndrome. Nature Clinical Practice Rheumatology, 2008, 4, 454-455.	3.2	30
173	Neuroendocrine Dysfunction in Sjögren's Syndrome. NeuroImmunoModulation, 2008, 15, 37-45.	0.9	61
174	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the Rheumatic Diseases, 2007, 66, 732-739.	0.5	175
175	SS-B (La) AUTOANTIBODIES. , 2007, , 239-246.		0
176	Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. Journal of Autoimmunity, 2007, 29, 219-228.	3.0	177
177	Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Practice and Research in Clinical Rheumatology, 2007, 21, 989-1010.	1.4	101
178	Sjögren's Syndromeâ€"Study of Autoantigens and Autoantibodies. Clinical Reviews in Allergy and Immunology, 2007, 32, 238-251.	2.9	102
179	Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. Journal of Autoimmunity, 2006, 26, 165-171.	3.0	122
180	Risk factors for lymphoproliferation and mortality in Sjögren's syndrome. Future Rheumatology, 2006, 1, 607-616.	0.2	0

#	Article	IF	CITATIONS
181	The Role of Chaperone Proteins in Autoimmunity. Annals of the New York Academy of Sciences, 2006, 1088, 52-64.	1.8	32
182	Anti-LA/SSB antiidiotypic antibodies in maternal serum: A marker of low risk for neonatal lupus in an offspring. Arthritis and Rheumatism, 2006, 54, 2228-2234.	6.7	40
183	Autoantibodies to intracellular autoantigens and their B-cell epitopes: Molecular Probes to Study the Autoimmune Response. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 203-248.	2.7	40
184	Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmunity Reviews, 2005, 4, 8-15.	2.5	85
185	Zinc Ion Dependent B-Cell Epitope, Associated with Primary Sjogren's Syndrome, Resides within the Putative Zinc Finger Domain of Ro60kD Autoantigen:Â Physical and Immunologic Properties. Journal of Medicinal Chemistry, 2004, 47, 4327-4334.	2.9	13
186	The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clinica Chimica Acta, 2004, 340, 1-25.	0.5	61
187	Idiotype–anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289–308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. Journal of Autoimmunity, 2003, 21, 17-26.	3.0	35
188	Linear epitopes of two different autoantigens-La/SSB and myelin basic proteinâ€"with a high degree of molecular similarity, cause different humoral immune responses. Journal of Autoimmunity, 2003, 21, 47-57.	3.0	8
189	Unmasking the Anti-La/SSB Response in Sera From Patients With Sjogren's Syndrome by Specific Blocking of Anti-idiotypic Antibodies to La/SSB Antigenic Determinants. Molecular Medicine, 2002, 8, 293-305.	1.9	48
190	Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Molecular Medicine, 2002, 8, 293-305.	1.9	16
191	Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. Journal of Rheumatology, 2002, 29, 2129-35.	1.0	80
192	?Lymphoid? chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sji¿½gren's syndrome patients: Possible participation in lymphoid structure formation. Arthritis and Rheumatism, 2001, 44, 408-418.	6.7	165
193	Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjogren Syndrome. Medicine (United States), 2000, 79, 241-249.	0.4	170
194	Sjögren's Syndrome: Autoantibodies to Cellular Antigens. International Archives of Allergy and Immunology, 2000, 123, 46-57.	0.9	63
195	Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. American Journal of Medicine, 2000, 108, 198-204.	0.6	133
196	Autoantibodies to La/SSB in Patients with Primary Sjögren's Syndrome (pSS) are Associated with Upregulation of La/SSB mRNA in Minor Salivary Gland Biopsies (MSGs). Journal of Autoimmunity, 1999, 13, 429-434.	3.0	29
197	Sjögren's Syndrome. Advances in Experimental Medicine and Biology, 1999, , 127-134.	0.8	50
198	A major Sm epitope anchored to sequential oligopeptide carriers is a suitable antigenic substrate to detect anti-Sm antibodies. Journal of Immunological Methods, 1998, 220, 59-68.	0.6	28

#	Article	IF	CITATIONS
199	Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus. Correlation with anemia. Arthritis and Rheumatism, 1997, 40, 2212-2216.	6.7	74
200	Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis and Rheumatism, 1996, 39, 767-772.	6.7	230
201	Autoantibodies to hmg-17 nucleosomal protein in autoimmune rheumatic diseases. Arthritis and Rheumatism, 1993, 36, 955-961.	6.7	28
202	Idiopathic retroperitoneal fibrosis: clinical features, treatment modalities, relapse rate in Greek patients and a review of the literature. Clinical and Experimental Rheumatology, 0, , .	0.4	1